Ebos Group (ASX:EBO) Short-Term Debt: A$108 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EBO Ebos Group Ltd ASX:EBO
80 GF Score
Price A$18.99
GF Value A$31.56
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group Short-Term Debt?

Ebos Group ASX:EBO +0.74% 80 Short-Term Debt is A$108 Mil as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 80/100 and a GF Value™ of A$31.56 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Ebos Group's Short-Term Debt for the quarter that ended in Dec. 2025 was A$108 Mil.

Ebos Group's quarterly Short-Term Debt declined from Dec. 2024 (A$106 Mil) to Jun. 2025 (A$16 Mil) but then increased from Jun. 2025 (A$16 Mil) to Dec. 2025 (A$108 Mil).

Ebos Group's annual Short-Term Debt increased from Jun. 2023 (A$42 Mil) to Jun. 2024 (A$773 Mil) but then declined from Jun. 2024 (A$773 Mil) to Jun. 2025 (A$16 Mil).

Ebos Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ebos Group Short-Term Debt Related Terms

Ebos Group Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ebos Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group Short-Term Debt Chart

Ebos Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.51 332.31 41.91 773.48 15.76

Ebos Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.80 773.48 105.97 15.76 107.53
ASX:EBO
80GF Score
Ebos Group Ltd ASX:EBO
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$108 Mil mean?
Ebos Group (ASX:EBO) has a Short-Term Debt of A$108 Mil as of Dec. 2025.
Is Ebos Group's Short-Term Debt too high?
Ebos Group's current Short-Term Debt is A$108 Mil. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Short-Term Debt compare to MCK and CAH?
Ebos Group's Short-Term Debt of A$108 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Distribution company?
A good Short-Term Debt depends on the Medical Distribution industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ebos Group's current Short-Term Debt is A$108 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.56, compared to a current price of A$18.99 — trading 39.8% below its estimated fair value. The current Short-Term Debt is A$108 Mil. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Short-Term Debt is A$108 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$18.99 is trading 39.8% below its estimated GF Value™ of A$31.56. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • Short-Term Debt: A$108 Mil
  • GF Value™: A$31.56 vs. price of A$18.99 (39.8% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score

Get the complete analysis for ASX:EBO

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$18.99
Price
A$31.56
GF Value